Drug metabolic kinetics

Author(s):  
Nagendra Sai Kumar Achanta ◽  
Kuldeep Rajpoot ◽  
Rakesh Kumar Tekade
Keyword(s):  
2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Changpeng Wang ◽  
Siwei Zhang ◽  
Yuefei Zou ◽  
Hongzhao Ma ◽  
Donglang Jiang ◽  
...  

Abstract Background Some neuropsychological diseases are associated with abnormal thiamine metabolism, including Korsakoff–Wernicke syndrome and Alzheimer’s disease. However, in vivo detection of the status of brain thiamine metabolism is still unavailable and needs to be developed. Methods A novel PET tracer of 18F-deoxy-thiamine was synthesized using an automated module via a two-step route. The main quality control parameters, such as specific activity and radiochemical purity, were evaluated by high-performance liquid chromatography (HPLC). Radiochemical concentration was determined by radioactivity calibrator. Metabolic kinetics and the level of 18F-deoxy-thiamine in brains of mice and marmosets were studied by micro-positron emission tomography/computed tomography (PET/CT). In vivo stability, renal excretion rate, and biodistribution of 18F-deoxy-thiamine in the mice were assayed using HPLC and γ-counter, respectively. Also, the correlation between the retention of cerebral 18F-deoxy-thiamine in 60 min after injection as represented by the area under the curve (AUC) and blood thiamine levels was investigated. Results The 18F-deoxy-thiamine was stable both in vitro and in vivo. The uptake and clearance of 18F-deoxy-thiamine were quick in the mice. It reached the max standard uptake value (SUVmax) of 4.61 ± 0.53 in the liver within 1 min, 18.67 ± 7.04 in the kidney within half a minute. The SUV dropped to 0.72 ± 0.05 and 0.77 ± 0.35 after 60 min of injection in the liver and kidney, respectively. After injection, kidney, liver, and pancreas exhibited high accumulation level of 18F-deoxy-thiamine, while brain, muscle, fat, and gonad showed low accumulation concentration, consistent with previous reports on thiamine distribution in mice. Within 90 min after injection, the level of 18F-deoxy-thiamine in the brain of C57BL/6 mice with thiamine deficiency (TD) was 1.9 times higher than that in control mice, and was 3.1 times higher in ICR mice with TD than that in control mice. The AUC of the tracer in the brain of marmosets within 60 min was 29.33 ± 5.15 and negatively correlated with blood thiamine diphosphate levels (r = − 0.985, p = 0.015). Conclusion The 18F-deoxy-thiamine meets the requirements for ideal PET tracer for in vivo detecting the status of cerebral thiamine metabolism.


2011 ◽  
Vol 24 (8) ◽  
pp. 997-1005 ◽  
Author(s):  
Tao Xu ◽  
Dirk Mayer ◽  
Meng Gu ◽  
Yi-Fen Yen ◽  
Sonal Josan ◽  
...  

Author(s):  
Sara C. Humphreys ◽  
Babak Basiri ◽  
Armina Abbasi ◽  
Brooke M. Rock
Keyword(s):  

2017 ◽  
Vol 11 ◽  
pp. 117954681773111 ◽  
Author(s):  
Lúcia Helena Bonalume Tácito ◽  
Lilian Nakachima Yamada ◽  
Marcela Augusta de Souza Pinhel ◽  
Juan Carlos Yugar-Toledo ◽  
Dorotéia Rossi Silva Souza

This study confirms the association of risk factors for coronary artery disease (CAD) and the apoE polymorphisms, specifically related to the APOE*4 allele, with coronary disease in postmenopausal women. Significantly altered values of the lipid profile were found in patients when compared with controls, independent of the presence of the APOE*4 allele. However, the controls showed higher high-density lipoprotein cholesterol (HDL-C) levels and reduced triglyceride (TG) levels, differing significantly from patients. In this case, the study of subgroups, considering the APOE*3/3 and APOE*3/4 genotypes, suggests that the APOE*4 allele is not implicated in the variations of the lipid profile of patients and determined an increase in the production levels of HDL-C and a reduction in TG highly benefiting the control group compared with APOE*3/3 genotype. The metabolic kinetics of TG, although with the same pattern between groups, and the presence of the APOE*4 allele are suggested to be associated with accelerated clearance compared with APOE*3 allele in non-CAD group.


1999 ◽  
Vol 367 (2) ◽  
pp. 225-232 ◽  
Author(s):  
Hongxiang Liu ◽  
James A. Bee ◽  
Peter Lees

2000 ◽  
Vol 279 (4) ◽  
pp. E920-E926 ◽  
Author(s):  
Wenjun Z. Martini ◽  
Oivind Irtun ◽  
David L. Chinkes ◽  
Robert E. Barrow ◽  
Robert R. Wolfe

The primary goal of this study was to investigate the effects of glucose infusion on surfactant phosphatidylcholine (PC) metabolic kinetics in the lungs. A new stable isotope tracer model was used in which [1,2-13C2]acetate and uniformly labeled [U-13C16]palmitate were infused in 12 normal overnight-fasted pigs to quantify lung surfactant kinetics with or without glucose infusion (24 mg · kg−1 · min−1). With glucose infusion, the rate of surfactant PC incorporation from de novo synthesized palmitate increased from the control value of 2.1 ± 0.2 to 15.5 ± 1.9 nmol PC-bound palmitate · h−1 · g wet lung−1 ( P < 0.05), whereas the incorporation rate from plasma preformed palmitate decreased from the control value of 20.9 ± 1.9 to 11.6 ± 1.1 nmol palmitate · h−1 · g wet lung−1 ( P < 0.05). The palmitate composition in lamellar body surfactant PC increased from the control value of 61.7 ± 2.1% to 75.9 ± 0.6% ( P < 0.05). The surfactant PC secretion rate decreased from the control value of 239.0 ± 26.1 to 81.9 ± 5.3 nmol PC-bound palmitate · h−1 · g wet lung−1 ( P < 0.05). We conclude that, whereas surfactant secretion was inhibited by glucose infusion, neither total surfactant PC synthesis nor the surfactant PC pool size was significantly affected due to an increased reliance on de novo synthesized fatty acids.


Sign in / Sign up

Export Citation Format

Share Document